Renal Failure (Jan 2021)

Effects of parathyroidectomy on plasma PTH fragments and heart rate variability in stage 5 chronic kidney disease patients

  • Huimin Chen,
  • Wenkai Ren,
  • Zhanhui Gao,
  • Ming Zeng,
  • Shaowen Tang,
  • Fangyan Xu,
  • Yaoyu Huang,
  • Lina Zhang,
  • Ying Cui,
  • Guang Yang,
  • Hanyang Qian,
  • Wenbin Zhou,
  • Chun Ouyang,
  • Xueyan Gao,
  • Jing Zhang,
  • Yujie Xiao,
  • Baiqiao Zhao,
  • Jing Wang,
  • Anning Bian,
  • Fan Li,
  • Huiting Wan,
  • Wei Gao,
  • Xiaoyun Wang,
  • Changying Xing,
  • Xiaoming Zha,
  • Ningning Wang

DOI
https://doi.org/10.1080/0886022X.2021.1931318
Journal volume & issue
Vol. 43, no. 1
pp. 890 – 899

Abstract

Read online

Introduction Circulating intact parathyroid hormone (iPTH) levels include full-length (1-84) PTH and long C-PTH fragments, but primarily (7-84) PTH, which have been reported to have antagonistic effects on the bones and kidneys. However, their effects on the cardiovascular system remain unclear. In this study, the relationships between the plasma PTH fragments levels and heart rate variability (HRV) in stage 5 chronic kidney disease (CKD5) patients are explored. Furthermore, the effects of parathyroidectomy (PTX) on the above indices are investigated. Methods In this cross-sectional study, 164 healthy controls and 354 CKD5 patients, including 208 secondary hyperparathyroidism (SHPT) subgroup with PTX, were enrolled. Circulating (7-84) PTH levels were calculated by subtracting plasma (1-84) PTH levels from iPTH levels. The HRV parameters were measured using a 24-hour Holter. Results The baseline levels of plasma iPTH, (1-84) PTH, and (7-84) PTH in the CKD5 patients were 930.40 (160.65, 1792.50) pg/mL, 448.60 (99.62, 850.45) pg/mL, and 468.20 (54.22, 922.55) pg/mL, respectively. In the CKD5 patients, plasma (1-84) PTH levels were independently correlated with the standard deviation of the normal-to-normal R-R intervals (SDNN) and the standard deviation of the five-minute average of the normal R-R intervals (SDANN). With a median follow up time of 6.50 months after PTX in the SHPT patients (n = 30), improved SDNN and SDANN markers were related with decreased (1-84) PTH levels. Furthermore, an improved SDNN was related with decreased (7-84) PTH levels. Conclusions The CKD5 patients’ baseline (1-84) PTH levels were correlated with the SDNN and SDANN. After PTX, an improved SDNN was related with decreased (1-84) PTH and (7-84) PTH levels, while improved SDANN was related with decreased (1-84) PTH levels. No antagonistic effects of (1-84) PTH and (7-84) PTH on HRV were found in the CKD5 patients.

Keywords